Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.Schedule for the Financial Results Press Release, Conference Call / Webcast 

  • 3Q Fiscal Year 2013 Financial Results Press Release
  • 5/14/2013 at 7:30 a.m. ET

  • 3Q Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013 at 11:00 a.m. ET

    1-888-427-9419

    1-719-457-2648

    8591699

  • 3Q Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013-5/21/2013

    1-888-203-1112

    1-719-457-0820

    8591699

  • Webcast Live and Replay Access
  • http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    2. Palatin Technologies To Present At The 25th Annual ROTH Conference
    3. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    9. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    11. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
    (Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers ... CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, ... Salimetrics’ SalivaLab , the relationship between insulin and other relevant biomarkers can be ...
    (Date:2/23/2017)... FRANCISCO , Feb. 23, 2017   ViaCyte, ... Type 1, a not-for-profit advocacy and education group for ... grant from Beyond Type 1 to support ViaCyte,s efforts ... other insulin-requiring diabetes.  For more than ... cell replacement therapies with a focus on the treatment ...
    (Date:2/22/2017)... Santa Clara, CA (PRWEB) , ... February 22, 2017 , ... ... is hosting a free AFM Luncheon for all SPIE attendees ... San Jose, CA, just one block from the San Jose Convention Center. The ...
    Breaking Biology Technology:
    (Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
    (Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
    (Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
    Breaking Biology News(10 mins):